- Therapeutic Development
- Vaccine Production
- Drug Discovery
mRNA CDMO Services Market was valued at USD 2,876.4 million in 2022 and is poised to grow at a 7.5% CAGR from 2024 to 2030. mRNA CDMO services provide the production of mRNA sequences based on computer-provided sequences, and custom-tailored services are provided for mRNA template design including UTR and codon optimization. The continuously growing pharmaceutical companies and extensive product launches are major factors for the market growth of mRNA CDMO services. The increasing incidence of cancer patients accelerates the research and development activities which is the major factor that drives the market.
The high impact of COVID-19 boosts vaccine production and outsourcing contract manufacturing organizations raising the overall demand in the market, CDMOs are gaining significant market traction through technological advancement and a specialised workforce, and the extensive demand for CDMOs generates lucrative opportunities in the market. the contract basis development become a major trend in the market extensive production of vaccines and biologicals is the major trend in the CDMO services market. High production costs associated with equipment and workforce hinder the market which become major restraints in the mRNA CDMO services market.
Fastest Growing Market
The increasing prevalence of cancer diseases and growing demand for pharmaceutical products across the world are the major market drivers in the mRNA CDMO Services Market during the forecast period. Contract Development and Manufacturing Organization (CDMO) become a fragmented market, resulting in a higher demand for pharmaceuticals market for rapid innovations to develop effective process solutions that enhance the drug development process, additionally, the rise in the incidence of genetic disorders increased the services market which is the major factor for the growth. Hence, this will drive the global market growth at a significant rate.
The mRNA CDMO services market size was valued at USD 2,876.4 million in 2022, growing at a 7.5% CAGR from 2023 to 2029.
The leading players in the mRNA CDMO Services Market are Eurofins Scientific, WuXi Biologics, Samsung Biologics, Catalent, Inc., Rentschler Biopharma SE, AGC Biologics, BioCina, Novasep, Recipharm AB, Siegfried Holding AG, Boehringer Ingelheim, and FUJIFILM Diosynth Biotechnologies
Historic years considered for the market study are 2019 through 2023, 2023 is considered as the base year for market estimation and the forecast presented from 2024 to 2030.